Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals.

Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals.
Clin Adv Hematol Oncol. 2016 May;14 Suppl 7(5):10-11
Authors:
PMID: 27168105 [PubMed - as supplied by publisher]

Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research